Median Survival for Breast Cancer with Metastases to Bone, Liver, and Brain with Neurological Symptoms

Prognostic Factors Affecting Survival

The presence of multiple metastatic sites, including brain, significantly reduces survival compared to single-site metastasis, according to the National Cancer Institute and Neuro-Oncology 1, 2

For patients with HER2-positive breast cancer and good performance status, even with multiple brain metastases and coexisting extracranial metastases, median survival has been estimated at approximately 3 years, as reported by the Journal of Clinical Oncology 3
Targeted therapies may improve outcomes for HER2-positive disease, as noted by the Journal of Clinical Oncology 3

Surgery with postoperative radiation for accessible lesions, stereotactic radiosurgery (SRS) for smaller lesions, and whole-brain radiotherapy plus memantine with hippocampal avoidance are treatment options for patients with symptomatic brain metastases, according to the Journal of Clinical Oncology 3
The choice of local therapy depends on the number, size, location of metastases, and patient's performance status, as reported by the Journal of Clinical Oncology 4

Despite advances in treatment, the prognosis for patients with metastases to bone, liver, and brain with neurological symptoms remains poor, as noted by Neuro-Oncology 2